Julia Wang Named Chief Financial Officer
Beginning December 2,
2024
BURLINGTON, N.C., Nov. 19,
2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global
leader of innovative and comprehensive laboratory services,
announced today that Executive Vice President and Chief Financial
Officer (CFO) Glenn Eisenberg will
retire from the company and Julia
Wang will join on December 2,
2024, as Executive Vice President and Chief Financial
Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to
the CEO through April 2025 to ensure
a seamless transition of his current role and assist with strategic
initiatives underway within the company.
Ms. Wang brings deep global strategic and financial
experience across the diagnostic, pharmaceutical/biotech, medical
device and consumer products industries. Most recently, Ms. Wang
served as CFO of BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),
which she joined in June 2020 as
Senior Vice President, Enterprise Optimization and Deputy CFO.
While at BeiGene, she was instrumental in driving business
transformations through accelerating growth, nurturing innovation
and cultivating a culture of sustainable operating
efficiencies.
"I want to thank Glenn for a transformative 10 years as
Labcorp's CFO," said Schechter. "Under his leadership, Labcorp has
more than doubled its revenues from organic growth and
acquisitions, while delivering double-digit compound
annual total shareholder returns. He has developed a very
strong team and has been instrumental in helping us achieve our
strategic objectives. Also, during his tenure, Labcorp has
completed approximately 100 acquisitions, investing around
$11 billion and returning over
$6 billion to shareholders through
share repurchases and dividends. I look forward to working
with Glenn on the CFO transition and key strategic
initiatives. I wish him the best on his retirement and appreciate
his leadership and dedication to Labcorp."
Added Schechter, "Julia brings the right mix and diversity of
expertise in diagnostics and drug development as well as
pharmaceutical and biotech to lead our financial team into
Labcorp's next phase of growth. We will benefit from Julia's
extensive healthcare and consumer sector experience, strategic
insights and operating rigor as we continue to create and
unlock value for our shareholders and fulfill our mission to
improve health and improve lives."
"I have long admired Labcorp as a trusted brand and am thrilled
to join Labcorp as CFO and see clear opportunities to continue
executing on our strategy to help deliver better outcomes for
patients," said Ms. Wang. "No doubt Labcorp offers a
mission-driven, collaborative culture that delivers compelling
value for patients, employees and shareholders. I look forward to
working with Glenn to ensure a seamless transition and partnering
with Adam to position Labcorp to continue to provide excellent
value to shareholders and accelerated growth as we enter 2025 with
momentum."
About Ms. Julia Wang
Prior to joining BeiGene in 2020, Ms. Wang served as Senior Vice
President, Global Business Finance and Corporate Planning at
Alexion Pharmaceuticals. Before Alexion, she held leadership
positions at Quest Diagnostics, including Vice President of U.S.
Regional Finance and Enterprise Commercial, and Vice President of
Finance, Value Creation. Earlier in her career, Ms. Wang held
senior leadership roles at Johnson & Johnson as CFO of
various operating businesses in medical device and
pharmaceuticals. Previously, she also led finance initiatives at
PepsiCo. Ms. Wang earned her MBA from Fuqua
School of Business at Duke
University and her BA in British Language and Literature
from Shandong Normal University.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and
comprehensive laboratory services that helps doctors, hospitals,
pharmaceutical companies, researchers and patients make clear and
confident decisions. We provide insights and advance science to
improve health and improve lives through our unparalleled
diagnostics and drug development laboratory capabilities. The
company's more than 67,000 employees serve clients in approximately
100 countries, provided support for 84% of the new drugs and
therapeutic products approved in 2023 by the FDA, and performed
more than 600 million tests for patients around the world. Learn
more about us at www.labcorp.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/labcorp-cfo-glenn-eisenberg-announces-plans-to-retire-302309270.html
SOURCE Labcorp Holdings Inc